Drug intelligence / Profile preview

EB-101

Development stage: Preclinical
Lead developer: Elastin Biosciences
Modality: Small Molecules
Administration: Topical

Overview

EB-101 is a small molecule drug candidate being developed by Elastin Biosciences for the treatment of cardiovascular diseases. Developed using a cheminformatics-driven platform, EB-101 is designed to restore tissue structural integrity by boosting the production of elastin and fortifying the elastin-based extracellular matrix. This mechanism aims to counteract the degradation of elastin, which is a critical pathological feature in various cardiovascular conditions. As of early 2024, EB-101 has successfully completed proof-of-concept studies and is currently in the IND-enabling phase of development.

Targets

ELN (Elastin)

Beyond the preview

Go deeper on EB-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB-101.

Explore the full profile